TARA Biosystems Announces Launch of Cardiotype.Fo, Best-in-Class In Vitro Assay for Assessment of Cardiac Contractility

Thursday, September 27, 2018 Heart Disease News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Sept. 27, 2018 /PRNewswire/ -- TARA Biosystems Inc. a company offering "heart-on-a-chip" tissue models for drug

discovery and development applications, announced today the launch of Cardiotype.Fo, the best-in-class in vitro system for assessment of cardiac contractility. Contractility of heart muscle tissue is a critically important measure of cardiac function
and is used routinely to evaluate the safety of biopharmaceutical drug candidates and the efficacy of therapies under development for the treatment of cardiomyopathy and heart failure.

TARA Biosystems offers bioanalytical testing services on its proprietary cardiac tissue engineering platform known as Biowire™ II. The Biowire™ II platform promotes the maturation of induced pluripotent stem cell (iPSC) derived cardiomyocytes into engineered cardiac tissues that mimic structural, functional and genetic characteristics of mature human cardiac tissue. These physiologically relevant in vitro tissue models enable early cardiac risk assessment of drug discovery candidates and accelerate discovery efforts for novel heart medicines via disease modeling and phenotypic screening capabilities. 

Leveraging TARA's Biowire™ II platform, Cardiotype.Fo is the only in vitro assay on the market that is capable of directly measuring contractile force, rate of contraction and rate of relaxation of engineered human cardiac tissues. The launch of Cardiotype.Fo follows from successful evaluations of the assay with more than a dozen biopharmaceutical partners to date.

Biowire™ II was recently recognized by Frost & Sullivan's 2018 Technology Innovation Award as the leading Heart-On-A-Chip solution in North America.  Frost & Sullivan's Technology Innovation Award recognizes groundbreaking products with innovative features and functionality that are gaining rapid acceptance in the market.

The TARA team will be showcasing Cardiotype.Fo at Booth #212 at the upcoming 2018 Safety Pharmacology Society (SPS) Annual Meeting in Washington, D.C., (Sept. 30-Oct. 3, 2018). Please stop by our booth to learn more about Cardiotype.Fo or contact us in advance to schedule a private meeting with our team (BD@tarabiosystems.com).

About TARA Biosystems

TARA Biosystems Inc. provides predictive, in vitro human cardiac tissue models for use in drug discovery and risk assessment. TARA Biosystems offers a high fidelity solution that is based on human iPSC derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiac functionality, including contractile force. The TARA platform allows pharma to access human cardiac information on therapeutics candidates earlier in the drug development cycle. For more information, please visit www.tarabiosystems.com.

Media ContactDonna Seedonna@tarabiosystems.com (917) 512-3037

Cision View original content:http://www.prnewswire.com/news-releases/tara-biosystems-announces-launch-of-cardiotypefo-best-in-class-in-vitro-assay-for-assessment-of-cardiac-contractility-300720037.html

SOURCE TARA Biosystems Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store